Amgen Inc. (AMGN) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

New Phase‑3 VESALIUS‑CV subgroup data show Repatha reduces first major cardiovascular events by 29 % in high‑risk diabetic patients, strengthening its cardiometabolic positioning and potentially driving future label expansion; watch upcoming regulatory filings and reimbursement updates. The analysis covered 6,002 individuals with elevated LDL‑C and no prior heart attack or stroke, reinforcing the benefit when added to statins, confirming additive benefit in a large, well‑defined population and potentially broadening the drug’s clinical use; watch for FDA guidance on label changes. The 29 % reduction aligns with earlier cardiovascular benefit data, but this subgroup analysis specifically targets high‑risk diabetes, a key market segment, which could enhance payer interest in covering Repatha for diabetic patients and increase sales volume; watch payer reimbursement decisions in the next few weeks. The data may support a label expansion to include high‑risk diabetic patients, which could lift the drug’s market share in the cardiometabolic space; watch the timing of the label filing and regulatory response. Investors should note that the company is likely to file for label expansion soon, and a successful filing would broaden the patient base and improve revenue projections; watch the company’s earnings call for guidance on the filing timeline. The strong cardiovascular benefit may also impact Repatha’s competitive positioning against other PCSK9 inhibitors, potentially shifting market share toward Amgen if payers favor the expanded indication; watch competitor filings and market share data. The data reinforce Repatha’s safety profile in a high‑risk population, which could improve clinician confidence and prescribing rates; watch for any safety updates from regulatory agencies. The 6,002‑patient cohort provides robust evidence that may satisfy payers’ evidence requirements for coverage, potentially accelerating reimbursement decisions; watch upcoming payer coverage determinations. Overall, the new data strengthen Repatha’s cardiometabolic case and set the stage for potential label expansion, regulatory filings, and reimbursement updates in the next 1–10 trading days, which could positively influence the company’s valuation and sales outlook; watch regulatory announcements and payer responses.

AMGN|Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Exchange

NMS

Country

United States

Website

amgen.com

Symbol

AMGN

Description

Amgen Inc. is a global biotechnology company focused on the discovery, development, manufacturing, and delivery of human therapeutics. The company's core value proposition lies in its diverse portfolio of innovative medicines designed to treat a wide range of serious illnesses. Key therapeutic areas include immunology, oncology, cardiovascular disease, bone health, and nephrology, with flagship products such as Enbrel, Repatha, and Prolia. Amgen distributes its products through healthcare providers, pharmacies, and direct-to-consumer channels, establishing a broad market reach. Strategic collaborations with other pharmaceutical companies, such as AstraZeneca and Novartis, further enhance its product pipeline and market presence, solidifying its competitive position in the biotechnology landscape.

AMGN|Earnings Snapshot

Earnings Summary

Amgen Inc. is a global biotechnology company dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics across critical areas such as immunology, oncology, cardiovascular disease, bone health, and nephrology. Operating within the broader Healthcare sector, specifically the Drug Manufacturers - General industry, Amgen leverages a diverse portfolio of medicines and strategic collaborations to address serious illnesses and maintain a competitive edge. In its most recent reported quarters, Amgen demonstrated a mixed but generally positive earnings trend. For Q1 2026, the company reported an actual EPS of $5.15 against an estimate of $4.77, and revenue of $8.618 billion against an estimate of $8.571 billion, indicating a beat on both fronts. This followed a strong Q4 2025 where actual EPS was $5.29, exceeding the estimate of $4.83, and revenue reached $9.866 billion, surpassing the estimate of $9.662 billion. The preceding quarters of 2025 also showed actual EPS exceeding estimates, with Q3 2025 at $5.64 (vs $5.01 est.) and Q2 2025 at $6.02 (vs $5.28 est.). Revenue data is not consistently provided for earlier quarters, making a direct comparison difficult, but the trend suggests consistent EPS beats in the most recent periods. Historically, Amgen has shown a trajectory of growth, with recent quarters consistently beating analyst EPS expectations. The company has demonstrated a pattern of exceeding earnings estimates in its last four reported quarters, indicating a reliable performance against projections. While revenue estimates were not always available, the actual revenue figures in the most recent quarters have also trended upwards, supporting the positive earnings trend. Recent news highlights a significant leadership transition with the retirement of its CFO, Peter Griffith, and the appointment of Thomas Dittrich. While this signals a focus on succession planning, analysts maintain a positive outlook, with Piper Sandler reiterating an Overweight rating and a $427 price target, citing expected revenue growth from key products like Uplizna and Tepezza. Investors will be watching for the successful integration of the new CFO and continued sales momentum from its key drugs, as well as any impact from new safety warnings in Japan, to gauge future performance.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$5.59	-	-
Q1'26	$4.77	$5.15	+8.0%
Q4'25	$4.83	$5.29	+9.6%
Q3'25	$5.01	$5.64	+12.5%
Q2'25	$5.28	$6.02	+14.1%
Q1'25	$4.26	$4.90	+15.0%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$9.6B	-	-
Q1'26	$8.6B	$8.6B	+0.5%
Q4'25	$9.7B	$9.9B	+2.1%
Q3'25	-	$9.6B	-
Q2'25	-	$9.2B	-
Q1'25	-	$8.1B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

AMGN Stock Snapshot

AMGN is currently trading at $347.89, giving Amgen Inc. a market cap of 188.67B and a P/E ratio of 24.2. Today's range spans $345.08–$356.50, with shares opening at $348.76 and moving down $1.69 (0.5%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 81/100.

Over the past year AMGN has traded between $267.83 and $391.29 - the current price is +29.9% off the 52-week low and -11.1% from the high.

The earnings revision cycle for Amgen Inc. (AMGN) may be in an upward phase - large-cap Healthcare names (188.67B market cap) showing bullish technicals (68/100, BUY) alongside bullish sentiment (81/100) often see analyst target increases in the weeks following this kind of dual-signal alignment. Price: $347.89 (in the middle of its 52-week range). (P/E: 24.2) Range: $267.83–$391.29. The chart frequently leads the fundamental revision, and the chart is bullish.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (68/100) and news sentiment (81/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $347.89 (in the middle of its 52-week range), AMGN's position within the $267.83–$391.29 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.

News Sentiment Analysis

Sentiment gathered from recent headlines

81/100

Strong NegativeNeutralStrong Positive

BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Amgen presented new Phase 3 VESALIUS-CV subgroup data at the ADA 86th Scientific Sessions, showing a 29% reduction in first major cardiovascular events for high‑risk diabetes patients. The study included 6,002 participants with elevated LDL‑C and no prior heart attack or stroke, reinforcing Repatha®’s efficacy in a cardiometabolic population. Real‑world data released alongside the presentation highlighted significant treatment gaps in obesity and diabetes care, underscoring unmet needs that AMGN aims to address. These findings strengthen the company’s cardiometabolic portfolio and may influence future pricing and reimbursement discussions.

What did this article say?

Amgen’s stock closed at $349.58, close to current analyst targets, yet a fair‑value model indicates a potential upside of about $352 per share. Over the last month the share price gained 5.6%, while the 90‑day return fell 5.4%, highlighting short‑term volatility. The company’s 1‑year total shareholder return of 24% and 3‑year return of 75% underscore its long‑term performance. Key catalysts for traders include the upcoming earnings announcement and potential AI‑driven medicine initiatives.

What did this article say?

The European Commission granted marketing authorization for Amgen’s IMDYLLTRA, a T‑cell engager for extensive‑stage small cell lung cancer. The approval follows DeLLphi‑304, a Phase 3 study showing a 40 % reduction in death risk and over five months longer median overall survival versus standard chemotherapy. This milestone expands Amgen’s oncology portfolio into a previously untreatable indication and may drive future sales in the European market. Investors should watch for the U.S. FDA review and the commercial launch timeline.

What did this article say?

No summary available yet for this article.

What did this article say?

Amgen’s European Commission approval of IMDYLLTRA expands its oncology portfolio, targeting extensive‑stage small cell lung cancer after platinum‑based chemotherapy. The firm also showcased robust Phase 3 and real‑world data for UPLIZNA and TAVNEOS, bolstering their safety and disease‑control profiles in rare autoimmune conditions. These achievements reinforce Amgen’s positioning in high‑unmet‑need niches and may shift investor perception toward its specialty‑therapeutics pipeline. The company’s narrative now emphasizes differentiated mechanisms and long‑term evidence to attract clinicians and regulators.

What did this article say?

Amgen used its Jefferies investor conference to spotlight first‑quarter momentum, noting a 6% YoY revenue rise and 5% non‑GAAP EPS growth. The company highlighted 16 products with double‑digit sales growth and 17 products annualizing over $1 billion, underscoring a robust portfolio. MariTide, the obesity candidate, is positioned as a key 2026 launch, supported by AI‑driven development. Amgen frames 2026 as a springboard year to offset pressure from its denosumab franchise amid intensifying competition.

What did this article say?

Amgen Inc. (AMGN) participated in the Jefferies Global Healthcare Conference on June 4, 2026, presenting its latest strategic initiatives. Company executives, including Executive VP & CFO Peter Griffith, outlined progress on key drug pipelines and R&D investments. The presentation emphasized upcoming regulatory milestones and potential market expansion opportunities. Investors should note the disclosed guidance on upcoming product launches and the company’s focus on cost optimization. The conference also highlighted Amgen’s commitment to shareholder value through dividend enhancements and share repurchases.

What did this article say?

AMGN will present new data on rare autoimmune and inflammatory diseases at the EULAR 2026 Congress in London, potentially expanding its pipeline and market reach. The data could influence future regulatory discussions and investor expectations. The presentation offers a platform to showcase clinical outcomes and engage with rheumatology experts. Traders should watch for the specific disease indications and any subsequent guidance from the company.

What did this article say?

The European Commission has granted approval for Amgen’s IMDYLLTRA as a treatment for extensive‑stage small cell lung cancer. The decision follows the Phase 3 DeLLphi‑304 trial, which showed a 40% reduction in mortality versus standard chemotherapy. This approval expands Amgen’s oncology portfolio and may drive sales growth in the lung‑cancer segment. Investors should monitor the commercial rollout timeline and reimbursement negotiations in key markets.

What did this article say?

AMGN has secured European Union approval for its drug Imdylltra in extensive‑stage small cell lung cancer, following phase III data that demonstrated a 40% reduction in death risk. The approval expands the company’s oncology portfolio and positions Imdylltra as a potential new revenue driver in a competitive lung‑cancer market. The decision may accelerate the drug’s commercial rollout across EU member states and influence pricing negotiations with payers. Investors should monitor the timing of the EU launch and any subsequent regulatory updates that could affect market uptake.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

No summary available yet for this article.

What did this article say?

AMGN·Amgen Inc.

EPS

Revenue

AMGN Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More